Connected sleep devicemaker ResMed today released the AirSense 11, its latest CPAP machine iteration, which includes a host of new features to treat obstructive sleep apnea. The new machine has many ...

After Philips issued a recall in mid-June of nearly two dozen models of its continuous and noncontinuous ventilators, ResMed has eagerly stepped up to fill in the market gap left by Philips’ absence.

The last 12 months have been nothing short of a whirlwind for ResMed. After finding itself scrambling to pick up the slack left in the wake of Philips’ massive respiratory device recall last June, it ...

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...

Jan 29 (Reuters) - Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep apnea. The company ...

Alphabet subsidiary Verily is teaming up with well-known sleep company ResMed to form a new venture that will focus on developing sleep apnea treatments and connected health products. The latest ...

The “unlimited demand” for ResMed’s sleep apnea machines has given the San Diego, CA-based company the capital to become involved in some heavy-duty M&A. ResMed said it had signed a definitive ...

Loud snoring at night. Pauses in breathing followed by gasps for air while you’re asleep. Excessive daytime fatigue. Frequent nodding off in front of the TV or even when behind the wheel of a car.

GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds. ResMed (NYSE: RMD) finds itself in an investment limbo ...

Resmed has beaten expectations with $2 billion in second-quarter revenue and says weight loss drugs are actually boosting ...

ResMed is potentially undervalued, trading at a 31.65% discount from its 5Y average P/E ratio, with strong market leadership and untapped growth potential in OSA treatment. Projected 10-year EPS ...